TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT04260022: Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL

Sponsor: Ascentage Pharma Group Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 242 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT04260022 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04260022 Rescue Dossier →